“To study the serum angiotensin converting Enzyme level (ace) as a possible biomarker in Covid-19:” a one year cross sectional study at A tertiary care hospital.”

Abstract

The COVID-19 outbreak has claimed the lives of almost 2 million individuals. In the renin-angiotensin system, angiotensin-converting enzyme 2 (ACE2) is a counterregulatory enzyme that converts angiotensin-2 to Ang-(1-7) form. Several researches have looked into the relationship between ACE2 and COVID-19. Indeed, the antiinflammatory/ anti-oxidant action of the ACE2/Ang (1-7) system protects the lung from acute respiratory distress syndrome. SARS-Cov-2, on the other hand, can enter host cells via ACE2. ACE2 expression can be changed by a variety of variables, including hypertension, diabetes, and obesity, all of which can worsen COVID-19 infection. Furthermore, because androgens boost ACE-2 expression, males are at a higher risk of COVID-19 infection. Although reported figures showed that COVID-19 infection risks differed significantly between adults the explanation for the disparities remains unknown. Aims: To investigate serum angiotensin converting enzyme (ACE) levels as much as feasible Biomarker in patients with covid-19.